TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

TScan Therapeutics to Participate in the Cowen 43rd Annual Health Care Conference

By

TScan Therapeutics Announces Presentation at the H.C. Wainwright Cell Therapy Virtual Conference

By

TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors

By

TScan Therapeutics Announces 2023 Clinical Plans and Highlights Recent Progress

By

TScan Therapeutics Presents Phase 1 Umbrella Trial in Progress on HA-1 (TSC-100) and HA-2 (TSC-101) at the 64th American Society of Hematology Annual Meeting 2022

By

TScan Therapeutics Named the Highest-Placed Midsize Biotechnology Company in The Top Places to Work for 2022 by The Boston Globe

By

TScan Therapeutics to Participate in the 5th Annual Evercore ISI HealthCONx Conference

By

TScan Therapeutics Presents Preclinical Data for Solid Tumor Program at the 37th Society for Immunotherapy of Cancer Annual Meeting

By

TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

By

TScan Therapeutics Announces Upcoming Virtual Investor Event

By